Is Nidan Laborator. overvalued or undervalued?

As of 18 September 2025, the valuation grade for Nidan Laborator. has moved from very attractive to attractive, indicating a shift in perception about its investment potential. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 13.62, an EV to EBITDA ratio of 7.14, and a Price to Book Value of 0.40, which suggest that the company is trading at a discount relative to its earnings and assets.
In comparison to its peers, Nidan Laborator. shows a significantly lower PE ratio than Apollo Hospitals, which stands at 71.62, and Max Healthcare, which has a PE ratio of 94.6. This highlights that Nidan is undervalued relative to these competitors. Additionally, while Nidan's ROCE is 3.44% and ROE is 2.90%, these figures are modest but indicate potential for improvement. Notably, the company's stock has underperformed the Sensex over the past year, with a return of -41.48% compared to the Sensex's 0.18%, reinforcing the notion that the stock may be undervalued in the current market environment.